Pliant Therapeutics, Inc. (PLRX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, CEO & Director | 1.08M | -- | 1966 |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer | 713.07k | 234.57k | 1977 |
| Mr. Mike Ouimette J.D. | Chief Legal & Compliance Officer and Secretary | 633.46k | -- | 1973 |
| Mr. Johannes P. Hull J.D. | Chief Business Officer | 654.52k | -- | 1975 |
| Dr. Eric A. Lefebvre M.D. | Chief Medical Officer | 762.34k | -- | 1964 |
| Dr. Rik Derynck Ph.D. | Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Dean Sheppard M.D. | Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Bill DeGrado Ph.D. | Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Hal Chapman M.D. | Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Ms. Delphine Imbert Ph.D. | Chief Technical Officer | -- | -- | -- |
Pliant Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 171
Description
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
May 5, 2025 at 10:59 AM UTC - May 9, 2025 at 12:00 PM UTC
Pliant Therapeutics, Inc. Earnings Date